Companies › Full-Life Technologies UK
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [225Ac]Ac-FL-020 anti-c-MET targeted radioligand therapy (alpha-particle emitter conjugate) | MET | Phase 1 | Metastatic Castration-resistant Prostate Cancer; Solid Tumor | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06492122 | [225Ac]Ac-FL-020 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Sep 2027 |
| NCT07873450 | [225Ac]Ac-FL-020 | Phase 1 | Solid Tumor | Oncology | Jun 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.